Tags

Type your tag names separated by a space and hit enter

A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge.
Nat Commun. 2020 08 14; 11(1):4081.NC

Abstract

The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.

Authors+Show Affiliations

Beijing Institute of Biotechnology, Beijing, China.State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Harbin, China.Beijing Institute of Biotechnology, Beijing, China.State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Harbin, China.Beijing Institute of Biotechnology, Beijing, China.State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Harbin, China.Beijing Institute of Biotechnology, Beijing, China.Beijing Institute of Biotechnology, Beijing, China.Beijing Institute of Biotechnology, Beijing, China.Beijing Institute of Biotechnology, Beijing, China.State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Harbin, China.Beijing Institute of Biotechnology, Beijing, China.Beijing Institute of Biotechnology, Beijing, China.Beijing Institute of Biotechnology, Beijing, China.State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Harbin, China.Beijing Institute of Biotechnology, Beijing, China.Beijing Institute of Biotechnology, Beijing, China.Beijing Institute of Biotechnology, Beijing, China.State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Harbin, China.Beijing Institute of Biotechnology, Beijing, China.Beijing Institute of Biotechnology, Beijing, China.Beijing Institute of Biotechnology, Beijing, China.Beijing Institute of Biotechnology, Beijing, China. houlihua@sina.com.State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Harbin, China. buzhigao@caas.cn.Beijing Institute of Biotechnology, Beijing, China. cw0226@foxmail.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32796842

Citation

Wu, Shipo, et al. "A Single Dose of an Adenovirus-vectored Vaccine Provides Protection Against SARS-CoV-2 Challenge." Nature Communications, vol. 11, no. 1, 2020, p. 4081.
Wu S, Zhong G, Zhang J, et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):4081.
Wu, S., Zhong, G., Zhang, J., Shuai, L., Zhang, Z., Wen, Z., Wang, B., Zhao, Z., Song, X., Chen, Y., Liu, R., Fu, L., Zhang, J., Guo, Q., Wang, C., Yang, Y., Fang, T., Lv, P., Wang, J., ... Chen, W. (2020). A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nature Communications, 11(1), 4081. https://doi.org/10.1038/s41467-020-17972-1
Wu S, et al. A Single Dose of an Adenovirus-vectored Vaccine Provides Protection Against SARS-CoV-2 Challenge. Nat Commun. 2020 08 14;11(1):4081. PubMed PMID: 32796842.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. AU - Wu,Shipo, AU - Zhong,Gongxun, AU - Zhang,Jun, AU - Shuai,Lei, AU - Zhang,Zhe, AU - Wen,Zhiyuan, AU - Wang,Busen, AU - Zhao,Zhenghao, AU - Song,Xiaohong, AU - Chen,Yi, AU - Liu,Renqiang, AU - Fu,Ling, AU - Zhang,Jinlong, AU - Guo,Qiang, AU - Wang,Chong, AU - Yang,Yilong, AU - Fang,Ting, AU - Lv,Peng, AU - Wang,Jinliang, AU - Xu,Junjie, AU - Li,Jianmin, AU - Yu,Changming, AU - Hou,Lihua, AU - Bu,Zhigao, AU - Chen,Wei, Y1 - 2020/08/14/ PY - 2020/06/04/received PY - 2020/07/23/accepted PY - 2020/8/16/entrez PY - 2020/8/17/pubmed PY - 2020/8/26/medline SP - 4081 EP - 4081 JF - Nature communications JO - Nat Commun VL - 11 IS - 1 N2 - The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials. SN - 2041-1723 UR - https://www.unboundmedicine.com/medline/citation/32796842/A_single_dose_of_an_adenovirus_vectored_vaccine_provides_protection_against_SARS_CoV_2_challenge_ L2 - https://doi.org/10.1038/s41467-020-17972-1 DB - PRIME DP - Unbound Medicine ER -